US FDA Approves Abiomed’s Impella For Cardiogenic Shock Ahead Of Schedule
This article was originally published in Clinica
Executive Summary
US FDA has approved earlier than anticipated Abiomed’s Impella 2.5, Impella CP, Impella 5.0 and Impella LD transcatheter ventricular assist devices to provide treatment of ongoing cardiogenic shock.